Global and Regional Trends of Multiple Sclerosis Disability-Adjusted Life Years Rates: A 25-Year Assessment

Mansouri, Samaneh; Zayeri, Farid

doi:10.1159/000492819

Cited by 12 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of the low incidence and prevalence rates, MS is one of the leading causes of non-traumatic disability in young adults (World Health Organization [WHO] 2013). Interestingly, the global MS burden of disease, assessed by disabilityadjusted life years (DALY), has been recently reported to have a global downward trend 43 . This trend was found for both developed and developing countries, although MS DALY rates are about 25 higher in developed countries compared to developing ones.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal

Pinheiro

Guerreiro

Costa

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

Aims: To assess the cost-utility of cladribine tablets versus fingolimod in patients with highly active relapsing-remitting multiple sclerosis (RRMS) in Portugal. Methods: A 1-year cycle cohort-based Markov state transition model was developed to simulate disease progression, measured by Kurtzke Expanded Disability Status Scale (EDSS), relapses, and conversion to secondary-progressive MS (SPMS). Patients were assumed to remain on treatment until progression to EDSS level 7, conversion to SPMS, or complete loss of efficacy due to waning effect. Natural history was based on British Columbia Multiple Sclerosis registry, London Ontario database, UK MS Trust, and cladribine tablets clinical trial (CLARITY). Portuguese all-cause mortality was adjusted for the MS associated increased mortality. Clinical inputs for active treatments (disability progression and relapse rate) were estimated on a network meta-analysis. Utility weights were derived from UK-MS Survey and published literature. Resource consumption by EDSS and due to relapses was based on published literature, National DRG microdata and expert opinion. Unit costs were obtained from official sources. The analysis was conducted from payers' perspective, time horizon of 50 years and discount rate of 5%, for both costs and benefits. Uncertainty was assessed via probabilistic and deterministic sensitivity analyses. Results: Compared to fingolimod, cladribine tablets were associated with a delay in progression, resulting in a gain of 0.85 quality adjusted life years (QALYs) and a cost decrease of 25,935 e. Probabilistic sensitivity analysis resulted in a mean ICER of À31,781 e per QALY and was dominant in 98.7% of the simulations. Cladribine tablets were dominant across the scenario analyses tested. Conclusions: Treatment of highly active RRMS with cladribine tablets was less costly and more effective than treatment with fingolimod. Hence, it is a dominant strategy in the Portuguese setting. No conclusions can be drawn from the present study regarding other treatment options, in particular natalizumab and alemtuzumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal

Pinheiro

Guerreiro

Costa

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…Other similar studies have also shown a higher incidence rate of MS at an early age [7,40]. The disease onset in the early age leads to an increase in the number of years lived with disability (YLDs) and eventually to disability-adjusted life years (DALYs) [4,41,42].…”

Section: Discussionmentioning

confidence: 89%

Evidence of an Increased Prevalence of Multiple Sclerosis: A Population-Based Study of Tehran Registry during 1999–2018

Almasi‐Hashiani

Sahraian

Eskandarieh

2020

Preprint

View full text Add to dashboard Cite

Background: The epidemiological characteristics of multiple sclerosis (MS) have been investigated in various studies, which have revealed that the prevalence of MS varies across countries. The present study was conducted to investigate the longitudinal prevalence of MS in Tehran, Iran. Methods: The present population-based study was conducted in Tehran, the capital of Iran from 1999 to 2018 based on the annual report data provided by the Iranian MS Society (IMSS) registry system. The age-standardized and crude prevalence were estimated using population data presented by the Statistical Centre of Iran. Results: A total of 21,580 MS cases were registered and included in the analysis. Among the participant patients, 24.99% (5,393) and 75.01% (16,187) of cases were male and female, respectively. The mean age of MS onset was 28.8 years (S.D: 8.7). The age-standardized prevalence (ASP) of MS increased from 73.7 (95%CI: 72.1-75.2) per 100,000 people in 2006 to 137.6 (95% CI: 135.7-139.5) per 100,000 people in 2018. The ASP of MS in 2018 was estimated to be 67.9 (95%CI: 66.0-69.8) and 207.3 (95%CI: 204.0-210.7) per 100,000 people among males and females, respectively. The age-standardized female-to-male ratio of MS ranged from 3.7 (in 2010) to 2.06 (in 2017). Conclusion: The findings of this study suggested that the prevalence of MS in Tehran province is relatively high, and the occurrence of the disease is more common in the age groups under 40 years as compared with older-aged groups. In line with reports provided for various regions of the world, the prevalence of MS was higher among women. Similarly, the findings of this study revealed that the female-to-male ratio was 2.14 in 2018.

show abstract

“…The disease Fig. 1 The age-standardized sex ratio (female to male) of MS, Tehran, Iran, 2006-2018 onset in the early age leads to an increase in the number of years lived with disability (YLDs) and eventually to disability-adjusted life years (DALYs) [4,40,41].…”

Section: Discussionmentioning

confidence: 99%

Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999–2018

2020

View full text Add to dashboard Cite

Background: The epidemiological characteristics of multiple sclerosis (MS) have been investigated in various studies, which have revealed that the prevalence of MS varies across countries. The present study was conducted to investigate the longitudinal prevalence of MS in Tehran, Iran. Methods: The present population-based study was conducted in Tehran, the capital of Iran from 1999 to 2018 based on the annual report data provided by the Iranian MS Society (IMSS) registry system. The age-standardized and crude prevalence were estimated using population data presented by the Statistical Centre of Iran. Results: A total of 21,580 MS cases were registered and included in the analysis. Among the participant patients, 24.99% (5393) and 75.01% (16,187) of cases were male and female, respectively. The mean age of MS onset was 28.8 years (S.D: 8.7). The age-standardized prevalence (ASP) of MS increased from 73.7 (95%CI: 72.1-75.2) per 100,000 people in 2006 to 137.6 (95% CI: 135.7-139.5) per 100,000 people in 2018. The ASP of MS in 2018 was estimated to be 67.9 (95%CI: 66.0-69.8) and 207.3 (95%CI: 204.0-210.7) per 100,000 people among males and females, respectively. The age-standardized female-to-male ratio of MS ranged from 3.7 (in 2010) to 2.06 (in 2017). Conclusion: The findings of this study suggested that the prevalence of MS in Tehran province is relatively high, and the occurrence of the disease is more common in the age groups under 40 years as compared with olderaged groups. In line with reports provided for various regions of the world, the prevalence of MS was higher among women. Similarly, the findings of this study revealed that the female-to-male ratio was 2.14 in 2018.

show abstract

Global and Regional Trends of Multiple Sclerosis Disability-Adjusted Life Years Rates: A 25-Year Assessment

Cited by 12 publications

References 38 publications

Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal

Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal

Evidence of an Increased Prevalence of Multiple Sclerosis: A Population-Based Study of Tehran Registry during 1999–2018

Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999–2018

Contact Info

Product

Resources

About